Nrf2 protects stellate cells from Smad-dependent cell activation

Area of Science:

• Hepatology and cellular signaling
• Fibrosis research
• Antioxidant response mechanisms

Background:

• Hepatic stellate cells (HSCs) drive liver fibrosis by depositing extracellular matrix (ECM).
• HSC activation is triggered by factors like TGF-β1, PDGF, and oxidative stress.
• The role of the Nrf2/Keap1 antioxidant pathway in HSC activation remains unclear.

Purpose of the Study:

• To investigate the role of the Nrf2 pathway in HSC trans-differentiation during liver fibrosis.
• To determine if Nrf2 modulates HSC activation and its relationship with the TGF-β1/Smad pathway.

Main Methods:

• Nrf2 and Keap1 expression were repressed in HSCs using specific siRNAs.
• HSCs (primary and immortalized human) were exposed to Smad inhibitors, TGF-β1, and/or PDGF.
• Activation markers, proliferation, and migration were assessed in Nrf2-deficient and wild-type HSCs.

Main Results:

• Nrf2 knockdown induced HSC activation, evidenced by increased αSMA-positive cells and ECM gene expression (collagens, fibronectin).
• Reduced Nrf2 levels led to increased HSC migration and decreased proliferation.
• Nrf2-deficient HSC activation was mediated by the TGF-β1/Smad pathway and inhibited by Smad inhibitors.
• TGF-β1 induced stronger HSC activation markers in Nrf2-deficient cells compared to wild-type cells.

Conclusions:

• Nrf2 activation acts as a crucial brake on HSC activation.
• The Nrf2 pathway limits liver fibrosis by inhibiting the TGF-β1/Smad signaling cascade in HSCs.
• Targeting Nrf2 may offer a therapeutic strategy for liver fibrosis.